Phase III Trial of ICLUSIG^® (Ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph⁺ ALL, a Setting with No Targeted Treatments Approved in the US

Takeda announced that the Phase III PhALLCON trial met its primary endpoint, demonstrating that adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with ICLUSIG® (ponatinib) plus chemotherapy achieved higher rates of minimal residual disease-negative complete remission compared to imatinib.